Curriculum Vitae
`
`Name: Linda T. Vahdat, MD
`Date of CV preparation: 6/24/14
`
`
`
`Institution name, city and state Dates attended Year awarded
`
`
`Barnard College NY, NY
`Mt.Sinai Medical School, NY, NY
`UCCEM, Cayey Medical School
`Cayey, Puerto Rico
`
`Massachusetts Institute of Technology, 10/12-5/14
`Sloan School of Business, Cambridge, MA
`
`9/78-5/82
`9/85-5/87
`9/83-6/85
`
`
`
`
`
`5/1982
`5/1987
`
`6/2014
`
`A. GENERAL INFORMATION
`425 East 61 Street, 8th Floor
`Office Address
`
`New York, NY 10065
`Office Telephone:
`212-821-0644
`Office Fax:
`212-821-0578
`Home address:
`178 Nod HIll Road
`
`Wilton, CT 06897
`Home telephone:
`203-834-2978
`Cell phone:
`917-589-5489
`Beeper:
`17235
`Email:
`ltv2001@med.cornell.edu
`Citizenship:
`USA
`
`B. EDUCATIONAL BACKGROUND
`
`Degree
`
`
`BA
`
`MD
`
`
`
`
`
`MBA
`
`
`
`
`C. PROFESSIONAL POSTIONS AND EMPLOYMENT
`
`Post-doctoral training including residency/fellowship
`
`
`Title
`
`
`Medical Resident Mount Sinai Hospital, New York
`Fellow
`
`Medical Oncology /Hematology,
`
`
`
`
`Memorial Sloan-Kettering Cancer
`
`
`
`
` Center, New York, NY
`
`
`
`
`
`Academic positions (teaching and research)
`
`
`
` Institution name, city and state
`
`
`Title
`
`
`Assistant Professor of Medicine
`Columbia University
`
`Assistant Professor of Medicine Weill Cornell Medical College
`Associate Professor of Clinical Medicine, Weill Cornell Medical College
`3/31/2010
`Professor of Medicine, Weill Cornell Medical College
`
`Hospital positions (attending physician, if applicable)
`
`Title
`
`
`Institution name, city and state
`Assistant Attending New York Presbyterian Hospital, NY
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Institution name, city and state
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dates
`
`
`
`
`
`
`
`
`
`
`
`1987-90
`
`1991-94
`
`Dates
`1994-2002
`2002
`2003-
`
`4/1/2010- current
`
`
`
`
`
`Dates
`1994-2003
`
`IMMUNOGEN 2104, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`
`2
`Associate Attending New York Presbyterian Hospital, NY
`Attending
`
`New York Presbyterian Hospital, NY
`Employment (other than positions listed above)
`None
`
`D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE
`
`Licensure
`State
`
`
`New York
`
`
` DEA number: BV 4170089
`
` Board Certification
`
`Name of Specialty
`
`Internal Medicine
`Medical Oncology
`
`
`
`
`
`
`
`2003-current
`2010-current
`
`Number
`176537
`
`Date of Issue Date of last registration
`10/88
`7/31/13
`
`
`
`
`
`
`Board Certificate #
`
`
`
`
`
`
`
`131963
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date of Certification
`
`
`
`
`1990
`1995, 2005
`
`
`
` Malpractice insurance
` Do you have malpractice insurance: YES
` Name of provider: MCIC
` Premiums paid by: Weill Cornell Medical College
`
`E. PROFESSIONAL MEMBERSHIPS (medical and scientific societies)
`
`Member/officer
`
`American Society of Clinical Oncology (ASCO) 1994- current
`Member
` Education committee
`
`
`
`1994-2003
`
`
` Education Technology Assessment Subcommittee2001-2002
`Member
` Patient Communication Subcommittee
`
`2002-current
`Member
` Patients Living With Cancer (PLWC)
`2003-2009
`Associate Editor
` Program Committee-Breast- Adjuvant
`
`2006-2008
`Member
` Program Committee- Breast Adjuvant
`
`2007-2008
`Track Leader
`Program Committee- ASCO Breast Cancer
`2009-2010
`Co-Chair
`Symposium
`
`
`2009-2012
`
`Health Services Research Committee
`Member
`2010-2012
`
`
`to International Affairs Committee
`Liason
`Member American Society for Blood and Marrow
`1996-2002
`
`
` Transplantation Breast Cancer Working Comm. 1996-2002
`Southwest Oncology Group (SWOG)
`Member
`
`
`
` Bone marrow and Stem Cell Transplant Committee 1996-2002
`
`
`
` Breast Cancer Committee
`
` 1996-2002
`American Association for Cancer Research
`
`Member
`1997-current
`Member NY Cancer Consortium
`
`
`2002-2011
`
`
`Breast Cancer Committee
`
` 2002-2011
`
`
`Executive Committee
`
`
`
`2005-2011
`American Cancer Society Steering Committee
`
`Member
`2005
`
`
`
`
`Compliance in Breast Cancer Treatment
`Member Cancer and Leukemia Group B (CALGB)
`Susan B Komen for the Cure
`Member
`
`
`
`
`
`
`
`Name of Organization
`
`
`
`Dates held
`
`
`
`
`
`
`
`2003- current
`2008-2010
`
`IMMUNOGEN 2104, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`3
`Promise Grants Review Committee ($8 million/ grant)
`Department of Defense, Breast Cancer Research
`Program Grant Review Committee
`
`2008
`
`
`
`
`
`
`
`
`Member
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date awarded
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1998
`1999
`2002
`2003
`2004
`2005
`2006
`2007
`
`2008
`2009
`2010
`
`2011
`
`2011
`2011
`
`F. HONORS AND AWARDS
`
`Name of award
`
`Outstanding Service Award from Cancer Care, Inc.
`Outstanding Service Award from Cancer Care, Inc.
`Physician of the Year, Cancer Care, Inc.
`
`
`Outstanding Service Award from Cancer Care, Inc.
`Outstanding Service Award from Cancer Care, Inc.
`Outstanding Service Award from Cancer Care, Inc.
`Outstanding Service Award from Cancer Care, Inc.
`Margie Filter Individual Achievement Award from
`Cancer Care of Connecticut, Inc.
`
`
`
`
`Advanced Research Foundation
`
`
`
`
`Advanced Research Foundation
`
`
`
`
`ASCO Statesman Award
`
`Scientific Research and Advancements in Breast Cancer Award
`
`From Susan G Komen for the Cure
`
`
`
`
`Margery Price Annual Breast Cancer Symposium Award from Mount
`Sinai School of Medicine
`
`
`
`
`
`
`Advanced Research Foundation
`
`
`
`
`
`
`G. INSTITUTIONAL/HOSPITAL AFFILIATION
`
`
`
`Primary Hospital Affiliation: NY Presbyterian Hospital
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dates
`
`1995-2002
`
`1997
`
`1998-2002
`
`1994-current
`
`1994-2002
`1994-2002
`1994-2002
`
`
`H. EMPLOYMENT STATUS
`
`Name of Employer(s): Weill Cornell Medical College
`
`I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT
`
`Teaching (list courses and your role)
`
`
`
`Preceptor, Medical Oncology course for second year medical
`students, Columbia University College of Physicians and Surgeons
`
`Preceptor, Clinical Clerkship in Medicine for third year medical
`students, Columbia University College of Physicians and Surgeons
`
`Course Director, Medical Oncology Clerkship
`
`Regular lectures to housestaff and fellows on breast cancer
`new cancer therapy modalities
`
`
`
`
`Clinical Care
`Attending on Bone Marrow Transplant Service: 3 months/year at CPMC
`Attending on Columbia Presbyterian Oncology Service: one month/year
`Attending on Bone Marrow Transplant Service CPMC: 3 months/year
`
`IMMUNOGEN 2104, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`
`4
`Attending on Bone Marrow Transplant Service WMC: 1 month/year
`Attending on WMC Oncology Service: one to two months/year
`
`
`
`
`
`2002-2005
`2003-current
`
`Administrative duties (including committees)
`Fellowship Selection Committee, Columbia University Division of Oncology
`Length of Stay Reduction Committee, Columbia University,
`
`
` Department of Medicine
`
`
`
`
`
`
`
`Director, Autologous Transplant Program
`1996-2002
`
`
`
`
`
` for Breast Cancer Columbia University
`1998-2001
`
`
`
`
`Faculty Council
`
`
`
`2002-current
`Medical Director, Breast Cancer Research Program of Weill Cornell
`Chief, Solid Tumor Oncology Service Weill Cornell Medical College
` 10/2011- current
`
`
`
`1994-2002
`
`1995
`
`
`
`
`
` 1994-current
`
`
`
`
`
`
`
`Research
`Principal Investigator on multiple clinical research studies for metastatic and high risk for
`recurrence breast cancer. These include high dose chemotherapy with stem cell support,
`immunotherapy, phase I to III breast cancer clinical trials with new agents, supportive care trials,
`and translational studies with laboratory collaborators at WCM, MSKCC and Rockefeller
`university. I have set the direction of the breast cancer research program for WCMC since 2002
`and have mentored junior faculty, fellows, residents and medical students. I am currently
`integrating across disciplines an integrated research direction of the Solid Tumor Service at
`WCMC.
`
`
`
`Formal Mentorship
`Abby Siegel, MD, Research Year after residency
`Rahki Naik. WMC student with GCRC Fellowship
`Victoria Blinder, MD
`
`
`
`Stephanie Jeske, MD
`
`
`
`Karen Barker Carlson, MD PhD
`
`
`Sarika Jain MD
`
`
`
`
`Nancy Chan, MD
`
`
`
`
`
`Current Percent Effort (%) Does the activity involve WCMC students/researchers? (Yes/No)
`Teaching
`15
`
`Y
`Y
`
`Clinical Care
`40
`
`Y
`Y
`Administration
`20
`
`N
`N
`Research
`25
`
`Y
`Y
`
`TOTAL:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1999-2000
`
`2004-2005
`
` 2006-2008
` 2008
`
`2007- 2011
`
`2010- 2012
`
`2012-2014
`
`
`
`100%
`
`
`
`J. RESEARCH SUPPORT (PAST AND PRESENT)
`
`Past Support
`
`
`Michael Cohen Breast Clinical Scholar Award
`
`PI: Antman
`
`
`
`
`Major Goal: to foster the development of junior faculty
`
`RO1
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 9/01/94 to 8/31/97
` 50,000. 30 % effort
`
` 1/1/1994 -12/31/98
`
`IMMUNOGEN 2104, pg. 4
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
` 1/1/94-12/31/99
` 5% effort
`
`
`5
`MDR Gene Therapy for Drug Resistance in Breast Cancer 5% effort
`PI: Arthur Bank
`
`
`
`
`
`
`
`
`Major Goal: to transduce peripheral blood stem cells with the MDR gene in order to prevent
`subsequent myelsuppression
`from chemotherapy
`in patients undergoing high dose
`chemotherapy with stem cell support.
`Role: investigator
`
`
`
`
`RO1,
`Biology of Hematopoietic Progenitors
`PI: Arthur Bank
`Major goal: to evaluate the safety and feasibility of transducing CD34+ cells with the MDR gene
`in breast cancer patients undergoing high dose chemotherapy with stem cell support for
`metastatic breast cancer.
`Role: investigator
`
`1/1/98-12/31/98 PI:
`Herbert Irving Comprehensive Cancer Center Program Pilot Award
`Robert Fine
`
`
`
`
`
` 20,000 5%effort
`Major Goal: Investigate the relationship of Bax, BCL2, BAD, BCLxl and PTEN and cyclin D 1 on
`outcome in a cohort of breast cancer patients who underwent high dose chemotherapy with
`stem cell support.
`Role: co-Investigator
`
` 1/1/2000-12/31/2001
`
`
`
`
`
`Sindab/Avon Foundation
` 50,000. 10% effort
`
`
`
`
`
`PI: Vahdat
`
`Major Goal: Evaluate the role of insulin, IGFR and IGFR BP3 in African American pre-
`menopausal women with and without breast cancer compared to Hispanic and Caucasian pre-
`menopausal women with breast cancer.
`
` 1/1/20002-12/31/2002
`
`
`
`
`
`Avon Foundation
` 50,000. 10% effort
`
`
`PI: Hank Juo MD, Ph.D.
`Major Goal: investigate single nucleotide polymorphisms that could predict for the development
`of chemotherapy induced peripheral neuropathy in breast cancer patients
`Role: co-Investigator
`
`
`
` 1/1/2002-12/31/2002
`
`
`
`
`
`Avon Foundation
`
` 50,000. 15% effort
`
`
`
`
`PI: Casilda Balmaceda
`Major Goal: Investigated the role of glutamine in attenuating or preventing the development of
`taxane induced peripheral neuropathy.
`Role: co-Investigator
`
` 12/15/2002-12/14/2003
`
`
`Breast Cancer Alliance of Greenwich
`
` $60,000 10% effort
`
`
`PI: Vahdat
`
`
`
`
`Major Goal: This project is a phase 2 study of tetrathiomolybdate (TM), an antiangiogenesis
`agent, for women with breast cancer at high risk of relapse.
`
`
` 1/1/2003-12/31/2005
`
`
`
`
`Peripheral Neuropathy Assoc
` 25,000. 5% effort
`
`
`
`
`PI: Vahdat
`
`
`
`Major Goal: This project is a randomized trial of glutamine to prevent peripheral neuropathy in
`breast cancer patients receiving paclitaxel chemotherapy. Correlatives are designed to help
`understand mechanisms behind the development of peripheral neuropathy.
`Role: PI
`
`
`
`
`
`
`
`
`
`
`
`IMMUNOGEN 2104, pg. 5
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`6
`
`
`
`
`
`
`
` 7/1/2004-6/31/2007
`
` 50,000 (annual)
`
`
`
`
`
`
`
`
`
`
`
`Clinical Scholar Award (WMC)
`
`
`
`
`
`
`
` 1/1/2005-12/31/2006
`
`Cancer Research and Treatment Fund, Inc.
`
` 28,000.
`
`PI: Vahdat
`
`
`
`
`
`Major Goal: This award supports infrastructure in the research program.
`
` 01/01/2006-6/30/09
`
`
`
`
`
`Anbinder Foundation
` 83,333 5% effort
`
`
`
`
`PI: Vahdat
`
`
`Major Goal: This grant supports several projects geared towards understanding the role of
`circulating hematopoietic progenitor cells in the natural history of breast cancer.
`Role: PI
`
`Clinical Scholar Award (WCMC)
`
`
`
`
`
`
`
` 05/01/2006-04/30/2010
`
`
`
`Susan G Komen Foundation
` EWOF2. 10% effort Major
`
`
`
`PI: Vahdat
`
`
`
`Goal: To assess the safety and tolerability of tetrathiomolybdate in patients with breast cancer at
`high risk of tumor recurrence and to evaluate the effect of tetrathiomolybdate on the circulating
`surrogate markers of angiogenesis.
`
` 1/1/2008-12/31/2009
`
`
`
`
`
`NY Community Trust
`PI: Vahdat $22,500 (annual) 10%
`“Phase II study of tetrathiomolybdate in women with high risk of breast cancer recurrence”
`Major Goal: This proposal addresses the unmet need of women with breast cancer at high risk
`of relapse that have no additional treatment options after completion of standard therapy. This
`grant helps to support correlative science.
`
` 1/1/2008-12/31/2009
`
`
`
`Cancer Research and Treatment
`
` $50,000
`
`
`
`PI: Vahdat,
`
` Major Goal: This award supports infrastructure in the research program.
`
` 7/1/2007-6/30/2010
`
` 50,000 (annual).
`
`
`
`01/01/2007-12/31/2010
`
`
`
`
`Bristol Myers Squibb Foundation
`PI: Vahdat
`
` $360,000 (total) 10%
`Major Goal: This project is a translational study with Rockefeller University to understand, on an
`ultrastructural level, chemotherapy induced peripheral neuropathy in women with breast cancer.
`
`
`
`Susan G. Komen Breast Cancer Foundation 8/14/2008-8/13/2011
`PI: Lyden
`
`
`
`
` $200, 000 (annual) 4%
`“The prognosis and therapeutic implications of bone marrow-derived progenitor cell”
`Major goal: To understand the contribution of VEGF R1+ cells and its contribution to trafficking
`metastases.
`Role: Co-Investigator
`
`12/01/2009-11/30/2010
`
`Stephen and Madeline Anbinder Foundation
` $50,000
`
`PI: Vahdat
`
`
`
`
`
`
`Major Goal: To perform microarrays to elucidate the angiogenic switch in a small cohort of
`patients that relapsed on the TM clinical study.
`
`Starr Cancer Consortium
`
`
`
`
`
`
`
`
`
`
`
`8/01/2010-7/31/2012
`
`IMMUNOGEN 2104, pg. 6
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`7
`
`
`$600,000 (annual)10%
`
`
`
`
`
`
`
`PI: Chan
`“Large-scale analysis of the epigenetic landscape underlying breast cancer metastasis”
`Major goal: to define the metastatic epigenome
`Role: Co- Principal Investigator
`
`11/1/2010-10/31/2012
`
`
`
`
`
`NY Community Trust
`$60,000 (annual)
`
`
`
`
`
`PI: Vahdat
`
`Major goal: To conduct an extension study of Phase II study of TM is women with breast cancer
`at high risk of relapse
`
`10/1/2010-9/30/2012
`
`
`
`Cancer Research and Treatment, Inc.
`$50,000
`
`
`
`PI: Vahdat
`
`
`
`
`Major goal: To support the clinical research infrastructure of the breast cancer research program
`
`Manhasset Women’s Coalition against breast cancer (awarded) 12/1/2012-11/30/2012
`PI: Vahdat
`
`
`
`
`
`
`
`$50,000
`Major goal: To support the phase II trial of TM in women with breast cancer and understand the
`effect of TM on the process of lung metastases in pre-clinical models
`Role: PI
`
`01/01/2011-12/31/2013
`
`
`
`
`
`The Avon Foundation
` $9,091.00
`
`
`
`
`
`PI: Chan
`
`
`Major goal: Clinical impact of highly promising biomarkers for distant failure derived from large-
`scale analysis of the breast cancer metastasis. Project focuses on optimization of a predictive
`epigenomic signature for breast cancer metastasis
`Role: Co- Principal Investigator
`
`
`
`Current Support:
`
`
`Department of Defense Era of Hope
`DOD Breast Cancer Research Program
`PI: Chan
`
`
`
`
`
`
`
`
`
`
`Project Goals/Specific Aims: Subaward from MSKCC - We are developing an epigenetic
`metastatic signature in breast cancer. My role (about 4% effort) will be to provide tumor
`samples from patients with breast cancer from an existing database and to assist with
`the analysis of the data.
`Role: Co- Principal Investigator
`
`Department of Defense Idea Award (award pending)
`PI: Mittal
`Major goal: Assess functional analysis and therapeutic potential of miR 708 in metastatic breast
`cancer
`Role: Co-Investigator
`
`
`
`
`
`03/01/2013- 2/28/2018
`
`$11,682 (subcontract) 0.5 Calendar
`
`
`
`
`
`7/1/2013-6/30/2015
`
`
`
`New York Community Trust,
`PI: Vahdat
`Title: Triple Negative Breast Cancer Clinic Development
`
`
`
`
`
`
`
`
`
`
`
`10/1/2013-9/30/2014
`
`IMMUNOGEN 2104, pg. 7
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`
`8
`Major Goal: This proposal addresses the unmet need of women with breast cancer. The
`goal is to develop a unified and systematic approach to research and treatment for this
`group in order to improve care and outcome.
`
`K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES
`
`Consulting Reviewer
`
`Journal of Clinical Oncology: 1995- 2009
`Clinical Cancer Research: 1998- 2012
`Cancer: 1995- 2007
`Breast Cancer Research and Treatment: 2002- 2009
`
`Invited Lectures at Large Meetings: (selected)
`
`August 4, 2014: Invited Plenary Speaker to Gordon Conference, “Rare cells in Circulation”,
`South Hadley, MA.” Affecting the tumor microenvironment through a copper depletion strategy:
`promoting tumor dormancy in breast cancer patients at high risk of relapse”.
`
`April 24, 2014: Invited speaker to 3rd International Breast Cancer Symposium in Seoul, Korea
`(invitation declined due to schedule conflict)
`
`November 7, 2013: Invited speaker to Chemotherapy Foundation Symposium NY, NY: The
`effect of copper depletion on the microenvironment of breast cancer patients at high risk of
`relapse.
`
`November 9, 2012: Invited speaker to Chemotherapy Foundation Symposium in NY, NY:
`Tackling the process of metastases in breast cancer: ramucirumab, 18F1 and other inhibitors of
`bone marrow derived progenitor cells.
`
`June 27, 2012: Invited speaker to International Latin American Conference in Bogota, Colombia:
`New therapies for Metastatic Breast Cancer
`
`January 11, 2011: Invited Speaker to the Annual meeting of the Israeli Society for Clinical
`Oncology and Radiation Therapy (ISCORT): Triple negative breast cancer: a work in
`progress
`
`August 18, 2010: Invited speaker to the Annual meeting of the Thai Breast Cancer Society in
`Bangkok, Thailand: “Beyond taxane therapy: new approaches in the management of metastatic
`breast cancer”.
`
`October, 2009: Annual Meeting Argentina Society of Medical Oncology in Buenos Aires,
`Argentina: “Updates in Triple Negative Breast cancer also known as “difficult to treat
`breast cancer”.
`
`October 2009 Taiwanese Society of Breast Medical Oncology in Taipei City, Taiwan:
`“Management of resistant breast cancer”.
`
`April 23, 2009: Turkish Society of Medical Oncology in Antalya, Turkey: Talks on “Role of
`Taxanes in the adjuvant breast cancer setting” and “New agents in Metastatic Breast Cancer”.
`
`October 2008: Mumbai India, Illume 2008. “Management of Resistant Breast Cancer”
`
`
`IMMUNOGEN 2104, pg. 8
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`
`9
`October 2008: Peruvian Society of Medical Oncology in Arequipa, Peru: “Emerging agents in
`metastatic breast cancer and “Triple Negative Breast Cancer: A work in progress”.
`
`September 2008: Brazilian Medical Oncology Congress in Rio de Janiero, Brazil: "HER 2 neu
`negative breast cancer: the evolution continues".
`
`July 4-8 2008: Invited speaker to the Annual Meeting in Wellington, New Zealand of the
`Australia New Zealand Breast Cancer Clinical Trials Group. “New Agents in Metastatic Breast
`Cancer", and "Chemotherapy induced Peripheral Neuropathy for the medical oncologist".
`
`April 14, 2008: Invited speaker to Buenos Aires, Argentina: "New therapies for
`resistant metastatic breast cancer".
`
`L. BIBLIOGRAPHY
`Peer-Reviewed Articles
`
`
`1. Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, Schneider J, Harrison M,
`Motzer R, Gilewski T, Hudis C, Gulati S, Norton L. Rapid administration of multiple
`cycles of high-dose myelosuppressive chemotherapy. J Clin Oncol 1993; 11:1144-1149.
`
`
`2. Crown J, Vahdat L, Fennelly D, Kritz A, Norton L. High-dose chemotherapy with
`hematopoietic support. Ann NY Acad Sci 1993; 698:378-388.
`
`
`3. Vahdat L, Wong E, Wile MJ, Rosenblum M, Foley K, Warrell RP Jr. Therapeutic and
`neurotoxic effect of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia.
`Blood 1994: 84:3429-3434.
`
`
`4. Vahdat L, Eardley A, Maslak P, Heller G, Scheinberg D, Warrell RP Jr. Early mortality
`and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis,
`low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patients
`treated with all-trans retinoic acid. Blood 1994; 84:3843-3849.
`
`
`5. Vahdat L, Raptis G, Fennelly D, Reich L, Harrison M, Tiersten A, Norton L, Crown JP.
`Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and
`peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer
`Research 1995; 1:1267-1273.
`
`
`6. Vahdat L, Raptis G, Fennelly D, Crown J. High dose chemotherapy of metastatic breast
`cancer. Cancer Invest 1995; 13(5): 505-10.
`
`
`7. Crown J, Raptis G, Hamilton N, Fennelly D, Vahdat L, Norton L. High-dose
`chemotherapy of breast cancer: current status and developmental strategies. Eur J
`Cancer 1995; 31(5): 809-11.
`
`
`8. Ross AA, Layton TJ, Ostrander AB, Passos-Coelho JL, Davis JM, Huelskamp AM, Noga
`SJ, Davidson NE, Kennedy MJ, Cooper BW, Gerson SL, Lazarus HM, Holland K, Gluck
`S, Moss TJ, Kaubish A, Vahdat L, Antman K. Comparative analysis of breast cancer
`contamination
`in mobilized and non-mobilized hematopoietic grafts. Journal of
`Hematotherapy 1996; Oct; 5(5): 549-52.
`
`
`9. Garrett TJ, Vahdat L, Kinne D. Systemic adjuvant therapy of breast cancer. J Surg
`Oncol 1997; 64:167-172.
`
`
`
`IMMUNOGEN 2104, pg. 9
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`
`
`10
`10. Papadopoulos KP, Ayello J, Tugulea S, Heitjan DF, Williams C, Reiss R, Vahdat LT,
`Suciu-Foca N, Antman KH and Hesdorffer CS. Harvest quality and factors affecting
`collection and engraftment of progenitor CD34+ cells in patients with breast cancer
`scheduled for high dose CTCb with chemotherapy and G-CSF mobilized peripheral
`blood progenitor cell support. J Hematotherapy 1997; 6: 61-68.
`
`
`11. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell
`M, Reiss R, Bank A, Antman K. A Phase I trial of retroviral-mediated transfer of the
`human MDR-1 gene as marrow chemoprotection in patients undergoing high-dose
`chemotherapy and autologous stem cell transplantation. J Clin Oncol 1998; 16:165-172.
`
`
`12. Vahdat LT, Papadopolous K, Balmaceda C, Fung B, Garrett TJ, Savage D, Tiersten A,
`Heitjen D, McGovern T, Dunleavy J, Kaufmen L, Antman KH, Hesdorffer C. Phase I trial
`of sequential high dose chemotherapy with escalating dose paclitaxel, melphalan and
`cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in
`women with responding metastatic breast cancer. Clin Cancer Research 1998; 4:1689-
`1695.
`
`
`13. Papadopoulos KP, Garvin JH, Fetell M, Vahdat LT, Garrett TJ, Savage DG, Balmaceda
`C, Bruce J, Sisti M, Isaacson S, De LaPaz R, Hawks R, Bagiella E, Antman KH,
`Hesdorffer CS. High-dose thiotepa and etoposide-based regimens with autologous
`hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
`Bone Marrow Transplantation 1998; 22:661-667.
`
`
`14. Lee RP, Oster MW, Balmaceda C, Hesdorffer CS, Vahdat LT, Papadopoulos KP.
`Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel. Ann
`Oncology 1999; 10: 1245-1247.
`
`
`15. Papadopoulos KP, Balmaceda C, Fetell M, Kaufman E, Vahdat LT, Bruce J, Sisti M,
`Isaacson S, De LaPaz R, Savage D, Troxel A, Antman KH, Hesdorffer CS. A phase I
`study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with
`hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
`J of Neuro-Oncology 1999; 44:155-162.
`
`
`16. Papadopoulos KP, Egorin, MJ, Huang M, Troxel AB, Kaufman E, Balmaceda CM,
`Vahdat LT, Hesdorffer CH. The pharmacokinetics and pharmacodynamics of high-dose
`paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic
`support in women with metastatic breast cancer. Cancer Chemother Pharmacol 2001;
`47: 45-50.
`
`
`17. Vahdat L, Papadopoulos K, Lange D, Leuin S, Rosenman S Kaufman E, Donovan D,
`Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D , Antman K,
`Hesdorffer C, Balmaceda C. Reduction of Paclitaxel-induced peripheral neuropathy
`with glutamine. Clin Cancer Research 2001; 7:1192-1197.
`
`
`18. Jacobson JS, Troxel AB, Evans, J, Klaus L, Vahdat L, Kinne D, Lo S, Moore A,
`Rosenman P, Kaufman EL, Neugut AI, Grann VR. Randomized trial of black cohosh for
`the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol
`2001; 19(10): 2739-45.
`
`
`19. Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E,
`Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer
`C. Phase II trial of sequential high dose chemotherapy with paclitaxel, melphalan and
`
`IMMUNOGEN 2104, pg. 10
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`
`
`11
`cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in
`women with responding metastatic breast cancer. Bone Marrow Transplantation 2002;
`30: 149-155.
`
`
`20. Nichols G, de Castro K, Wei L-X, Griffin M, Oratzi A, Murty VVVS, Troxel A, Vahdat L,
`Hesdorffer CS. Therapy-related myelodysplastic syndrome after autologous stem cell
`transplantation for breast cancer. Leukemia 2002; Sept16 (9): 1673-9.
`
`
`21. Tiersten A, Nelson C, Talbot S, Vahdat L, Fine R, Brafman L, Shriberg L, Antman K and
`Petrylak DP. A phase II trial of docetaxel and estramustine phosphate in refractory
`metastatic breast cancer. Cancer 2003; Feb 97 (3): 537-544.
`
`
`22. Savarese D, Savy G, Vahdat LT, Wischmeyer, Corey B. Prevention of chemotherapy
`and radiation toxicity with glutamine. Cancer Treatment Reviews 2003; Dec 29(6): 501-
`13.
`
`
`23. Clark A, Vahdat LT. Chemotherapy-induced palmar-plantar erythrodysesthesia
`syndrome (PPE): etiology and emerging therapies. Supportive Cancer Therapy 2004;
`July 1 (4): 213-218.
`
`
`24. Ocean A, Vahdat LT. Chemotherapy-induced peripheral neuropathy: Etiology and
`emerging therapies. Supportive Care in Cancer 2004; September 12 (9): 619-625.
`
`
`25. Skerret D, Mansukhani M, Moore EM, Bernstein DS, Vahdat L. Cytokine genotype
`polymorphisms: associations with primary breast carcinomas in women. Cancer
`Investigation 2005; 23:208-214.
`
`
`26. Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel A, Hesdorffer CS, Gooch CL.
`Glutamine as a neuroprotective agent in high dose paclitaxel-induced peripheral
`neuropathy: A clinical and electrophysiologic study. Clinical Oncology 2005; 17:271-276.
`
`
`27. Papadopoulos KP, Noguera-Irizarry W, Wiebe L, Hesdorffer DS, Garvin J, Nichols GL,
`Vahdat LT, Skerrett D, Bernstein D, Sharpe E, Savage DG. Pilot study of tandem high
`dose chemotherapy and autologous stem cell transplantation with a novel combination
`of regimens in patients with poor risk lymphoma. Bone Marrow Transplant 2005; Sep
`36(6) 491-7.
`
`
`28. Herbst R, Bajorin DF, Bleiber H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD,
`Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R,
`Schucter LM, Sweetenham JW, Vahdat LT, Vokes E, Winn RJ, Mayer RJ, American
`Society of Clinical Oncology. Clinical Cancer Advances 2005: major research advances
`in cancer treatment, prevention and screening—a report from the American Society of
`Clinical Oncology. J Clin Oncol 2006; Jan 1:24(1): 190-205.
`
`
`29. Tiersten A, Selleck M, Smith DH, Wertheim I, Kaufman E, Hershman D, Vahdat L,
`Savage DG, MacArthur RB, Hesdorffer, C. Phase I/II study of tandem cycles of high
`dose chemotherapy followed by autologous hematopoietic stem cell support in women
`with advanced ovarian cancer. Int J Gynecol Cancer 2006; Jan-Feb 16(1):57-64.
`
`
`30. Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Blaskovich M, Munster P,
`Lee P, Hoschander S, Hopkins U, Hershman D, Wright JJ, and Sebti S.. Targeted
`inhibition of farnesyltransferase in locally advanced breast cancer: a phase I-II trial
`
`IMMUNOGEN 2104, pg. 11
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`
`
`12
`incorporating tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin
`Oncol 2006; 24 (19): 3013-8.
`
`
`31. Conlin AK, Vahdat L. Dermatologic toxicity of ixabepilone. Anticancer Res 2006; 26(3B)
`2279-80.
`
`
`32. Huston TL, Pressman PI, Moore An, Vahdat L, Hoda SA, Kato M, Weinstein D,
`Tousimis E. The presentation of contralateral axillary lymph node metastases from
`breast carcinoma: a clinical management dilemma. Breast J 2007;Mar-Apr13 (2): 158-
`64.
`
`
`
`33. Vahdat LT, Cohen D, Zipin D, Lo KS, Donovan D, Sharpe D, Savage D, Tiersten A,
`Nichols G, Troxel A, Hesdorffer CS. Randomized trial of low dose interleukin 2 vs
`cyclosporine A and interferon g after high dose chemotherapy with peripheral blood
`progenitor support in women with high risk primary breast cancer. Bone Marrow
`Transplantation 2007; Aug 403:267-72.
`
`
`34. Naik R, Jin D, Chuang E, Gold E, Tousimis E, Christos P, de Dalmas T, Donovan D,
`Rafii S, Vahdat L. Circulating endothelial progenitor cells correlate to stage in patients
`with invasive breast cancer. Breast Cancer Treat 2008; Jan; 107(1): 133-8 (Epub 2007
`Feb 15).
`
`
`35. Roche H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP,
`Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Cure H. Phase II clinical trial of ixabepilone
`(BMS 247550), an epothilone B analog, as first-line therapy in patients with metastatic
`breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;
`Aug 10; 25(23): 3415-20.
`
`
`36. Thomas E, Tabernero JM, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT,
`Bunnell CA, Burris HA, Viens P, Peck R, Martin M. Phase II clinical trial of ixabepilone
`(BMS 247550), an epothilone B analog, in patients with taxane-resistant metastatic
`breast cancer. J Clin Oncol 2007; Aug 10; 25(23): 3399-406.
`
`
`37. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C,
`Mullaney B, Peck R, Hortobagyi GN. Efficacy and safety of ixabepilone (BMS-247550) in
`a phase II study of patients with advanced breast cancer resistant to an anthracycline, a
`taxane, and capecitabine. J Clin Oncol 2007; Aug 10; 25(23): 3407-14.
`
`
`38. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Eisenberg BL, Ganz
`PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R,
`Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ. American Society of
`Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer
`treatment, prevention, and screening—a report from the American Society of Clinical
`Oncology. J Clin Oncol 2007; 25(1) 146-62.
`
`
`39. Jhaveri K, Halperin P, Shin S, Vahdat L. Erythema nodosum secondary to aromatase
`inhibitor use in breast cancer: case reports and review of the literature. Breast Cancer
`Res Treat 2007; Dec 106(3): 315-8, (Epub 2007 Feb 15)
`
`
`40. Taylor C, Hershman D, Pegram M, Petrylak D, Taub R, Vahdat L, Cheng B, Knutson K,
`Clynes R. Treatment with trastuzumab induces anti-Her-2 humoral immunity. Clin
`Cancer Res 2007; Sep 1; 13 (17): 5133-43.
`
`IMMUNOGEN 2104, pg. 12
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`
`
`13
`
`
`41. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB,
`Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay
`P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer
`progressing after anthracycline and taxane treatment. J Clin Onc